MegaRobo Technologies has raised nearly $200 million in a new round that brings in Oman’s sovereign wealth fund. It has not said what the company is now worth.
The Chinese lab-automation company sent out the release on the evening of November 18, 2026, U.S. Eastern time. In Suzhou, where the release is datelined, it was already November 19. Bloomberg reported the round the same day.
Who put money in
The Oman Investment Authority joined the round. Existing backers Asia Investment Capital, Granite Asia and Sinovation Ventures put in more, and CMB International came in as a new investor. Some outlets call the Omani fund the lead. The release says only that OIA “joined” and doesn’t name a lead.
The release also gives no valuation, no share price and no breakdown of who paid what. If you hold shares already, you can’t work out from the outside how much you’ve been diluted.
That’s a lot of money to raise without a number attached.
How it compares with earlier rounds
According to MegaRobo’s funding announcement, the company has raised about $600 million to date. That total includes a Series C of nearly $300 million, co-led by Goldman Sachs Alternatives, Asia Investment Capital and Granite Asia. Using those rounded figures:
- Before this round: $600 million − $200 million = about $400 million raised
- After this round: about $600 million raised
- This round’s share of the total: $200 million ÷ $600 million = about one-third
The 2022 Series C made up about three-quarters of everything raised before this round ($300 million ÷ $400 million = 75%). The new round is roughly two-thirds that size ($200 million ÷ $300 million ≈ 67%).
Where the money goes
The money is going to core technology, overseas growth for what MegaRobo calls its AI for Science business, and systems that let AI work in more complex physical settings. The target markets are North America, Europe, the Middle East and Asia.
The product idea is simple to state. An AI model plans a test, robots run it, and the results decide what gets tested next. Its products have gone to more than 500 customers, mostly drug makers, biotechs and research institutions, and its Megalaxy Lab platform has served more than 200 of them. None are named.
It isn’t the only startup betting that AI needs real lab work behind it. Biomatter put its $18 million Series A into a lab of its own for AI-designed enzymes. In the same week as MegaRobo’s news, Boltz raised $110 million on the back of pharma paying per token for its models.
MegaRobo is also offering its lab to a public contest. Poreva Open is a protein design challenge run with Tencent Cloud and Twist Bioscience, and Megalaxy Lab will run wet-lab tests on more than 10,000 protein design sequences.
The IPO question
MegaRobo applied to list in Hong Kong in June 2025. That application has since lapsed, and the new release doesn’t mention a listing. So there’s no word on whether this money tides the company over until it files again or replaces the IPO.
